Safety Data Evaluation

Safety Data Evaluation is a systematic assessment process within the domain of pharmacovigilance and regulatory science that analyzes clinical and non-clinical data to identify, characterize, and interpret adverse events and other safety-related risks associated with a medicinal product, distinguishing it from general efficacy or quality evaluations by focusing exclusively on harm detection and risk-benefit profiling in support of Marketing Authorization Applications.

261

Publications

13.4K

Citations

1.6K

Authors

685

Institutions

Publications per year

2017–2026

113

Publications

261

Authors

1.6K

  1. ST
    Sengwee Toh

    Harvard University, United States

    3 publications · 72 citations

    3

    h-index

  2. HA
    H. Amy Xia

    Amgen (United States), United States

    3 publications · 154 citations

    3

    h-index

  3. TY
    Takayuki Yoshino

    National Cancer Center Hospital East, Japan

    3 publications · 577 citations

    3

    h-index

  4. JJ
    Joshua J. Gagne

    Brigham and Women's Hospital, United States

    3 publications · 72 citations

    3

    h-index

  5. SW
    Shirley Wang

    Brigham and Women's Hospital, United States

    3 publications · 72 citations

    3

    h-index

1–5 of 1.6K

Venues

  1. PubMed

    Repository · 8 publications · 556 citations

    8

    h-index

  2. Journal of Clinical Oncology

    8 publications · 1.3K citations

    8

    h-index

  3. Pharmacoepidemiology and Drug Safety

    7 publications · 172 citations

    7

    h-index

  4. Expert Opinion on Drug Safety

    7 publications · 140 citations

    7

    h-index

  5. Regulatory Toxicology and Pharmacology

    RTP · 6 publications · 304 citations

    6

    h-index

1–5